Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018

世界の癌/腫瘍プロファイリング市場

◆タイトル:Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018
◆商品コード:BT 2123
◆調査・発行会社:MarketsandMarkets
◆発行日:2013年9月
◆ページ数:173
◆レポート形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User(~5名)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate licence(社内共有可) USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界の癌/腫瘍プロファイリング市場"について調査・分析し、イントロダクション、エグゼクティブサマリー、市場の成長要因、阻害要因、バリューチェーン分析、市場環境分析、市場の動態、用途別分析、地域別分析、市場規模及び予測、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

Cancer/Tumor profiling is a promising market and is witnessing significant growth in the healthcare industry. It is poised to grow rapidly in a range of application areas, including biomarker discovery and prognosis. The global cancer/tumor profiling market is valued at $14.99 billion in 2013 and is expected to reach $35.03 billion by 2018.

A list of tests (for example, Barium X-ray, Blood tests, Bone marrow, Cystoscopy, Lumbar puncture) is available, used for diagnosing specific types of cancer. Also, there are different treatment options for cancer, including chemotherapy, hormone therapy, surgery, radiotherapy, bisphosphonates, bone marrow and stem cell transplants, and biological therapies. Despite the availability of different treatment options, profiling a cancer/tumor, that is, knowledge about a patient’s cancer/tumor profile may identify genomic alterations that will help the physician to guide the patient to a systemic therapy with a higher likelihood of success. This will rule out those that are unlikely to be successful, on an individual basis, thereby minimizing the trial and error process.

Every cancer cell has got its own pattern of active genes and proteins; therefore, molecular profiling tests for a number of different biomarkers in the DNA of a tissue sample will assist in better diagnosing and staging the cancer on an individual basis. This provides the doctors with better information to develop a personalized treatment plan for a patient, which is known as personalized medicine.

There are quite a number of research groups working on diverse applications of cancer/tumor profiling targeting different cancer types, particularly in studying key target molecules involved in the pathogenesis. Hundreds of research articles have been published and a lot of patents granted and filed for this field of biology.

The cancer/tumor profiling market is analyzed both in terms of qualitative, that is, technological and quantitative, that is, revenue and perspectives. The technological analysis includes discussion on the advantages and capabilities of cancer/tumor profiling technologies and the various applications where cancer/tumor profiling can find a strong position in the healthcare industry. The market revenue analysis includes market segmentation and the expected market position by 2018, with the projected growth rate.

The cancer/tumor profiling market is classified by geography, applications, technologies, and segment types. The technologies section is further segmented into Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray. Though personalized medicine is highlighted as the prime application area of cancer/tumor profiling, there are many opportunities in Diagnostics, Biomarker Discovery, Prognosis, and Research applications.

Besides a discussion on the properties and advantages of cancer/tumor profiling in the technological analysis, the basics on the correlation of cancer with genomics, proteomics, Metabolomics, and epigenetics are also discussed. Further, the research network including academic universities and biotech companies with their research contributions are also provided. The complete value chain of the cancer/tumor profiling market is schematically represented and the significance of each stakeholder has been briefed.

Apart from the technological and market analysis, the investor climate has been assessed by tracking the complete investor network and collecting data on funds/grants and investments made towards the cancer/tumor profiling. Insights on current and future technological investment trends have also been discussed.

The adoption and developmental potential of the cancer/tumor profiling technology market has been discussed on a geographic basis, that is, North America, Europe, Asia, and Rest of the World, by taking select countries that are poised to have a greater market value during the forecast period.

In brief, this research report provides:

A detailed description of the global technology developments and evolving trends in the cancer/tumor profiling field with key importance on research innovations, collaborative efforts, and investments for cancer/tumor profiling
An impact analysis of major drivers and restraints influencing the adoption and growth of the cancer/tumor profiling market from 2013 to 2018
Porter’s five forces analysis and GAP analysis
Market size – global market forecast for 2013-2018 analysis and strategic recommendations for technology/product developers
Competitive landscape, including key industry activities (for example, mergers, acquisitions, partnerships, collaborations, and agreements) and an analysis of key patents on the segment types.

Scope of the Report

This research report categorizes the global cancer/tumor profiling market into geography, applications, technologies, and segment types. The applications, technologies, and segments market is further broken down by geography, with an exhaustive revenue analysis for 2012 and 2013, as well as the forecast up to 2018.

Global Cancer/tumor profiling Market – By Geography

North America
Europe
Asia Pacific
Rest of the World (RoW)

Global Cancer/Tumor Profiling Market – By Applications

Personalized Medicine
Diagnostics
Biomarker discovery
Prognosis
Research applications

Global Cancer/Tumor Profiling Market – By Technologies

Next-Generation Sequencing
Quantitative PCR
Immunohistochemistry
FISH/CISH
Microarray

Global Cancer/Tumor Profiling Market – By Applications

Genomics
Proteomics
Metabolomics
Epigenetics

【レポートの目次】

Table Of Content

1 Introduction (Slide No. – 20)
1.1 Key Take-Aways
1.2 Logical Assumptions For This Study Based On Reliable Sources
1.3 Report Scope
1.4 Research Methodology
1.5 Key Data Points From Secondary & Primary Resources

2 Executive Summary (Slide No. – 27)

3 Tumor Profiling Technology Landscape (Slide No. – 31)
3.1 Technology Overview
3.2 Milestones In Cancer Research
3.3 Tumor Profiling Segments
3.3.1 Genomics
3.3.2 Proteomics
3.3.3 Metabolomics
3.3.4 Epigenetics
3.3.4.1 Epigenetic Genes Disturbed In Cancer Conditions
3.3.4.2 Cancers And Associated Epigenetic Disruptions
3.4 The Biological Organization Of The “-Omes”
3.5 Tumor Profiling Technologies
3.5.1 Next-Generation Sequencing (NGS)
3.5.2 Fluorescence/Chromogenic In Situ Hybridization (Fish/Cish)
3.5.3 Immunohistochemistry (IHC)
3.5.4 Microarray
3.5.5 Quantitative Pcr (QPCR)
3.6 Key Tumor Profiling Technological Innovations
3.7 Key Tumor Profiling Products & Services In The Market

4 Tumor Profiling Research Portfolio (Slide No. – 51)
4.1 Tumor Profiling Research Network

5 Value Chain Analysis (Slide No. – 54)
5.1 Overview
5.2 Key Stakeholders
5.3 Gap Analysis
5.4 Porter’s Five Forces Analysis

6 Market Landscape Analysis (Slide No. – 63)
6.1 “Tumor Profiling Technologies: Market Segmentation”
6.2 “Tumor Profiling Technologies: Global Impact
6.3 Market Forecast: Overview, 2013-2018
6.4 “Global Cancer Profiling: Market Revenue Forecast, 2013-2018″
6.4.1 “Global Cancer Profiling: Market Revenue, By Geography”
6.4.2 Global Cancer Profiling Market Share, By Geography
6.4.3 Global Cancer Profiling: Market Revenue, By Segment
6.4.3.1 Global Cancer Profiling: Market Share, By Segment
6.4.3.2 Genomics Market, By Region
6.4.3.3 Proteomics Market, By Region
6.4.3.4 Metabolomics Market, By Region
6.4.3.5 Epigenetics Market, By Region
6.4.4 Global Cancer Profiling Market Revenue, By Technology
6.4.4.1 Global Cancer Profiling Market Share, By Technology
6.4.4.2 Next-Generation Sequencing Market, By Region
6.4.4.3 Fluorescence/Chromogenic In Situ Hybridization Market, By Region
6.4.4.4 Immunohistochemistry Market, By Region
6.4.4.5 Quantitative Pcr Market, By Region
6.4.4.6 Microarray Market, By Region
6.4.5 Global Cancer Profiling Market Revenue, By Application
6.4.5.1 Global Cancer Profiling Market Share, By Application
6.4.5.2 Personalized Medicine Market, By Region
6.4.5.3 Biomarker Discovery Market, By Region
6.4.5.4 Diagnostics Market, By Region
6.4.5.5 Prognosis Market, By Region
6.4.5.6 Research Applications Market, By Region
6.5 Market Dynamics
6.5.1 Drivers
6.5.1.1 Tumor Profiling-Impact Analysis Of Drivers
6.5.2 Restraints
6.5.2.1 Tumor Profiling-Impact Analysis Of Restraints

7 Technology Adoption And Development Potential, By Geography (Slide No. – 114)
7.1 Geographic Adoption And Development Potential-Overview
7.2 North America
7.3 Europe
7.4 Asia
7.5 Rest Of The World (ROW)

8 Technology Investment Analysis (Slide No. – 122)
8.1 Investment Climate Assessment
8.2 Investor Network
8.3 Funds And Investments On Tumor/Cancer Profiling
8.4 Funds And Investments From Nih-By Fiscal Year
8.5 Funds And Investments From Nih-By Its Associated Institutes/Centers (2008 – 2013)
8.6 Top 10 Organizations To Receive Highest Funding From Nih During 2008-2013
8.7 Funds From The American Cancer Society As Of September 01, 2013 For Various Cancer Types
8.8 Insights On Current And Future Technology Investment Trends

9 Competitive Landscape Analysis (Slide No. – 136)
9.1 Competitive Landscape Analysis
9.2 Key Acquisitions/Partnerships/Agreements/Collaborations (2010-2013)
9.3 Technologies Available For Licensing & Acquisition For Stakeholders

10 Patent Analysis (Slide No. – 141)
10.1 Overview
10.2 Ip Strength Analysis-By Cancer Segments

11 Analyst Insights And Recommendations (Slide No. – 144)
11.1 Key Insights On The Market
11.2 Strategic Recommendations
11.3 Open Opportunity Invitations In The Field For Business Development

12 Company Profiles (Slide No. – 148)
12.1 Boreal Genomics, Inc.
12.2 Caris Life Sciences
12.3 Genomic Health, Inc.
12.4 Illumina, Inc.
12.5 Life Technologies Corporation
12.6 Neogenomics Laboratories
12.7 Oxford Gene Technology Ltd
12.8 Precision Therapeutics, Inc.
12.9 Biotheranostics
12.10 Proteome Sciences Plc
12.11 Agendia Nv
12.12 Nanostring Technologies
12.13 Rational Therapeutics
12.14 Oncopath Laboratory
12.15 Ribomed Biotechnologies

List Of Tables (22 Tables)

Tab - 1 Global Tumor Profiling Market, 2013-2018 ($Billion)
Tab - 2 Market Revenue, By Geography, 2013-2018 ($Billion)
Tab - 3 Global Market, By Segment, 2013-2018 ($Billion)
Tab - 4 Genomics Market, By Region, 2013-2018 ($Billion)
Tab - 5 Proteomics Market, By Region, 2013-2018 ($Billion)
Tab - 6 Metabolomics Market, By Region, 2013-2018 ($Billion)
Tab - 7 Epigenetics Market, By Region, 2013-2018 ($Billion)
Tab - 8 Global Cancer Profiling Market, By Technology, 2013-2018 ($Billion)
Tab - 9 Next Generation Sequencing Market, By Region, 2013-2018 ($Billion)
Tab - 10 Fluorescence/Chromogenic In Situ Hybridization Market, By Region, 2013-2018 ($Billion)
Tab - 11 Immunohistochemistrymarket, By Region, 2013-2018 ($Billion)
Tab - 12 Quantitative PCR, By Region, 2013-2018 ($Billion)
Tab - 13 Microarray Market, By Region, 2013-2018 ($Billion)
Tab - 14 Global Tumor Profiling Market, By Application, 2013-2018 ($Billion)
Tab - 15 Personalized Medicine Market, By Region, 2013-2018 ($Billion)
Tab - 16 Biomarker Discovery Market, By Region, 2013-2018 ($Billion)
Tab - 17 Diagnostics Market, By Region, 2013-2018 ($Billion)
Tab - 18 Prognosis Market, By Region, 2013-2018 ($Billion)
Tab - 19 Research Applications Market, By Region, 2013-2018 ($Billion)
Tab - 20 Funds By Nih & Its Associated Centers, 2008-2013 ($Million)
Tab - 21 Projects And Funds By Nih & Its Associated Centers, 2008-2013 ($Million)
Tab - 22 Projects And Funds From The American Cancer Society As Of Sep 01, 2013 ($Million)


List Of Figures (50 Figures)

Fig - 1 Global Tumor Profiling Market, 2013-2018 ($Billion)
Fig - 2 Porter’s Value Chain Analysis For The Cancer Profiling Market
Fig - 3 Global Cancer Profiling Market, 2013-2018 ($Billion)
Fig - 4 Market Revenue, By Geography, 2013-2018 ($Billion)
Fig - 5 Global Market, By Geography, 2012-2018
Fig - 6 Global Market By Segment, 2013-2018 ($Billion)
Fig - 7 Global Market: Growth Rate, By Segment, 2013-2018
Fig - 8 Global Market, By Segment, 2013-2018
Fig - 9 Genomics Market, By Region, 2013-2018 ($Billion)
Fig - 10 Genomics Market, By Region, 2013-2018
Fig - 11 Proteomics Market, By Region, 2013-2018 ($Billion)
Fig - 12 Proteomics Market, By Region, 2013-2018
Fig - 13 Metabolomics Market, By Region, 2013-2018 ($Billion)
Fig - 14 Metabolomics Market, By Region, 2013 - 2018
Fig - 15 Epigenetics Market, By Region, 2013-2018 ($Billion)
Fig - 16 Epigenetics Market, By Region, 2013-2018
Fig - 17 Global Cancer Profiling Market, By Technology, 2012-2018 ($Billion)
Fig - 18 Global Cancer Profiling Market, By Technology, 2012-2018
Fig - 19 Global Cancer Profiling Market, By Technology, 2013-2018
Fig - 20 Next Generation Sequencing Market, By Region, 2013-2018 ($Billion)
Fig - 21 Next-Generation Sequencing Market, By Region, 2013-2018
Fig - 22 Fluorescence/Chromogenic In Situ Hybridization Market, By Region, 2013-2018 ($Billion)
Fig - 23 Fluorescence/Chromogenic In Situ Hybridization Market, By Region, 2013-2018
Fig - 24 Immunohistochemistrymarket, By Region, 2013-2018 ($Billion)
Fig - 25 Immunohistochemistry Market, By Region, 2013-2018
Fig - 26 Quantitative Pcr, By Region, 2013-2018 ($Billion)
Fig - 27 Quantitative Pcr Market, By Region, 2013-2018
Fig - 28 Microarray Market, By Region, 2013-2018 ($Billion)
Fig - 29 Microarray Market, By Region, 2013-2018
Fig - 30 Global Cancer Profiling Market, By Application, 2012-2018 ($Billion)
Fig - 31 Global Cancer Profiling Market Share , By Application, 2012-2018
Fig - 32 Global Cancer Profiling Market, By Application, 2013-2018
Fig - 33 Personalized Medicine Market, By Region, 2013-2018 ($Billion)
Fig - 34 Personalized Medicine Market, By Region, 2013-2018
Fig - 35 Biomarker Discovery Market, By Region, 2013-2018 ($Billion)
Fig - 36 Biomarker Discovery Market, By Region, 2013-2018
Fig - 37 Diagnostics Market, By Region, 2013-2018 ($Billion)
Fig - 38 Diagnostics Market, By Region, 2013-2018
Fig - 39 Prognosis Market, By Region, 2013-2018 ($Billion)
Fig - 40 Prognosis Market, By Region, 2013-2018
Fig - 41 Research Applications Market, By Region, 2013-2018 ($Billion)
Fig - 42 Research Applicatons Market, By Region, 2013-2018
Fig - 43 Tumor Profiling-Market Dynamics
Fig - 44 Tumor Profiling Market Cagr, By Geography, 2013-2018
Fig - 45 Metabolomics Market, By Region, 2013-2018 ($Billion)
Fig - 46 Funding By Nih & Its Associated Centers, 2008-2013 ($Million)
Fig - 47 Funding By Nih & Its Associated Centers, 2008-2013 ($Million)
Fig - 48 Funding By American Cancer Society ($Million)
Fig - 49 Total No. Of Patents Filed, By Cancer Segments
Fig - 50 Cancer Segments Ip Share In 2013

★調査レポート[世界の癌/腫瘍プロファイリング市場] ( Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018 / BT 2123 ) 販売に関する免責事項
[世界の癌/腫瘍プロファイリング市場] ( Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018 / BT 2123 ) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆